Citations

Showing 10 of 108119 citations.

Clinical Theragnostic Relationship between Chemotherapeutic Resistance, and Sensitivity and miRNA Expressions in Head and Neck Cancers: A Systematic Review and Meta-Analysis Protocol
Shaw, Peter , Senthilnathan, Raghul , Kumarasamy, Chellan , Baxi, Siddhartha , Suresh, Deepa, Mani, Ravishankar Ram, Sivanandy, Palanisamy , Samiappan, Suja , Rajagopal, Mogana, Jayaraj, Rama , Ram, M. Ravishankar , Senthilnathan, Raghul , Shetty, Sameep , Ram, M Ravishankar , Sivanandy, Palanisamy , Rajagopal, Mogana , Jayaraj, Rama , Shaw, Peter , Raymond, Greg, Chandramoorthy, Harish C. , Krishnan, Sunil

Mayo Clinic

Genes | December 21, 2021 | Volume: 12 | Issue: 12 | Pages: 2029

10.3390/genes12122029 | PMID 34946979 Get It

Background: The microRNAs (miRNAs) are small noncoding single-stranded RNAs typically 19–25 nucleotides long and regulated by cellular and epigenetic factors. These miRNAs plays important part in several pathways necessary for cancer development, an altered miRNA expression can be oncogenic or tumor-suppressive. Recent experimental results on miRNA have illuminated a different perspective of the molecular pathogenesis of head and neck cancers. Regulation of miRNA can have a detrimental effect on the efficacy of chemotherapeutic drugs in both neoadjuvant and adjuvant settings. This miRNA-induced chemoresistance can influence the prognosis and survival rate. The focus of the study is on how regulations of various miRNA levels contribute to chemoresistance in head and neck cancer (HNC). Recent findings suggest that up or down-regulation of miRNAs may lead to resistance towards various chemotherapeutic drugs, which may influence the prognosis. Methods: Studies on miRNA-specific chemoresistance in HNC were collected through literary (bibliographic) databases, including SCOPUS, PubMed, Nature, Elsevier, etc., and were systematically reviewed following PRISMA-P guidelines (Preferred Reporting Items for Systematic Review and Meta-analysis Protocol). We evaluated various miRNAs, their up and downregulation, the effect of altered regulation on the patient’s prognosis, resistant cell lines, etc. The data evaluated will be represented in the form of a review and meta-analysis. Discussion: This meta-analysis aims to explore the miRNA-induced chemoresistance in HNC and thus to aid further researches on this topic. PROSPERO registration: CRD42018104657.
Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors
Blank, Christian U. , Wong, Deborah J. , Ho, Thai H. , Lee, Carrie B. , Bene‐Tchaleu, Fabiola, Zhu, Jing, Zhang, Xiaosong, Cha, Edward , Sznol, Mario , Ho, Thai , Bauer, Todd Michael , Zhang, Xiaosong

Mayo Clinic

Current Oncology | December 21, 2021 | Volume: 28 | Issue: 6 | Pages: 5466-5479

10.3390/curroncol28060455 | PMID 34940094 Get It

This Phase Ib study combined programmed death-ligand 1 inhibitor, atezolizumab, with other immunomodulatory agents in locally advanced and metastatic solid tumors. Arms B-D evaluated atezolizumab plus interferon-α, with/without vascular endothelial growth factor inhibitor, bevacizumab, in renal cell carcinoma (RCC) and other solid tumors. Arm B predominantly recruited patients with previously treated RCC or melanoma to receive atezolizumab plus interferon α-2b. Arm C investigated atezolizumab plus polyethylene glycol (PEG)-interferon α-2a in previously treated RCC. Arm D evaluated atezolizumab plus PEG-interferon α-2a and bevacizumab. Primary objectives were safety and tolerability; secondary objectives included clinical activity. Combination therapy was well tolerated, with safety profiles consistent with known risks of individual agents. The most frequent treatment-related toxicities were fatigue, chills, and pyrexia. The objective response rate (ORR) in arm B was 20.0% overall and 17.8% in patients with previously treated checkpoint inhibitor–naive RCC (n = 45). No responses were reported in arm C. The highest ORR in arm D was 46.7% in patients with treatment-naive RCC (n = 15). Data showed preliminary clinical activity and acceptable tolerability of atezolizumab plus interferon α-2b in patients with previously treated checkpoint inhibitor–naive RCC and of atezolizumab plus PEG-interferon α-2a and bevacizumab in patients with treatment-naive RCC.
Seminal Studies in Facial Reanimation Surgery: Consensus and Controversies in the Top 50 Most Cited Articles
Boonipat, Thanapoom , Al-Mouakeh, Ahmad , Muro-Cardenas, Jose , Stotland, Mitchell A. , Glass, Graeme E. , Asaad, Malke , Mardini, Samir

Mayo Clinic

Journal of Craniofacial Surgery | December 21, 2021 | Volume: 33 | Issue: 5 | Pages: 1507-1513

10.1097/scs.0000000000008436 | PMID 34930875 Get It

Abstract Facial paralysis can impair one'™s ability to form facial expressions that are congruent with internal emotion. This hinders communication and the cognitive processing of emotional experience. Facial reanimation surgery, which aims to restore full facial expressivity is a relatively recent undertaking which is still evolving. Due in large part to published techniques, refinements, and clinical outcomes in the scientific literature, consensus on best practice is gradually emerging, whereas controversies still exist. Taking stock of how the discipline reached its current state can help delineate areas of agreement and debate, and more clearly reveal a path forward. To do this, the authors have analyzed the 50 seminal publications pertaining to facial reanimation surgery. In longstanding cases, the free gracilis transfer emerges as a clear muscle of choice but the nerve selection remains controversial with prevailing philosophies advocating cross facial nerve grafts (with or without the support of an ipsilateral motor donor) or an ipsilateral motor donor only, of which the hypoglossal and nerve to masseter predominate. The alternative orthodoxy has refined the approach popularized by Gillies in 1934 and does not require the deployment of microsurgical principles. Although this citation analysis does not tell the whole story, surgeons with an interest in facial reanimation will find that this is a good place to start.
Track-structure modes in particle and heavy ion transport code system (PHITS): application to radiobiological research
Matsuya, Yusuke , Kai, Takeshi , Sato, Tatsuhiko , Ogawa, Tatsuhiko , Yoshii, Yuji, Parisi, Alessio , Liamsuwan, Thiansin , Parisi, Alessio , Hirata, Yuho

Mayo Clinic

International Journal of Radiation Biology | December 21, 2021 | Volume: 98 | Issue: 2 | Pages: 148-157

10.1080/09553002.2022.2013572 | PMID 34930091 Get It

In Vitro Antibiofilm Activity of Hydrogen Peroxide-Generating Electrochemical Bandage against Yeast Biofilms
Raval, Yash S. , Mohamed, Abdelrhman , Mandrekar, Jayawant N., Fisher, Cody, Greenwood-Quaintance, Kerryl E., Beyenal, Haluk, Patel, Robin , Fisher, Cody R. , Patel, Robin , Mohamed, A , Fisher, Cody , Raval, Yash S. , Mandrekar, Jayawant N., Fisher, Cody, Greenwood-Quaintance, Kerryl E., Beyenal, Haluk

Mayo Clinic

Antimicrobial Agents and Chemotherapy | December 21, 2021 | Volume: 66 | Issue: 2 | Pages: No page available

10.1128/aac.01792-21 | PMID 34930030 Get It

Wound infections are caused by bacteria and/or fungi. The presence of fungal biofilms in wound beds presents a unique challenge, as fungal biofilms may be difficult to eradicate.
A multicenter, retrospective study of accelerated venetoclax ramp‐up in patients with relapsed/refractory chronic lymphocytic leukemia
Davids, Matthew S. , Shadman, Mazyar , Parikh, Sameer A. , Ujjani, Chaitra S. , Crombie, Jennifer L. , Jiang, Dingfeng, Llamas, Cynthia , Lamanna, Nicole , Ujjani, Chaitra , Parikh, Sameer A , Shadman, Mazyar , Davids, Matthew S , Dai, Feng

Mayo Clinic

American Journal of Hematology | December 20, 2021 | Volume: 97 | Issue: 3 | Pages: No page available

10.1002/ajh.26444 | PMID 34929063 Get It

De novo mutations in childhood cases of sudden unexplained death that disrupt intracellular Ca 2+ regulation
Halvorsen, Matthew , Gould, Laura , Grant, Gariel, Moya, Raquel , Ackerman, Michael J. , Tester, David J. , Maurano, Matthew T. , Goldstein, David B. , Lin, Peter T. , Tsien, Richard W , Devinsky, Orrin , Wang, Xiaohan , Rabin, Rachel , Pappas, John , Devinsky, Orrin

Mayo Clinic

Proceedings of the National Academy of Sciences | December 20, 2021 | Volume: 118 | Issue: 52 | Pages: No page available

10.1073/pnas.2115140118 | PMID 34930847 Get It

Significance Approximately 400 United States children 1 y of age and older die suddenly from unexplained causes annually. We studied whole-exome sequence data from 124 “trios” (decedent child and living parents) to identify genetic risk factors. Nonsynonymous mutations, mostly de novo (present in child but absent in both biological parents), were highly enriched in genes associated with cardiac and seizure disorders relative to controls, and contributed to 9% of deaths. We found significant overtransmission of loss-of-function or pathogenic missense variants in cardiac and seizure disorder genes. Most pathogenic variants were de novo in origin, highlighting the importance of trio studies. Many of these pathogenic de novo mutations altered a protein network regulating calcium-related excitability at submembrane junctions in cardiomyocytes and neurons.
Discovery of small molecule guanylyl cyclase A receptor positive allosteric modulators
Sangaralingham, S. Jeson , Whig, Kanupriya , Peddibhotla, Satyamaheshwar , Kirby, R. Jason, Sessions, H, Maloney, Patrick , Hershberger, Paul, Mose-Yates, Heather, Hood, Becky , Vasile, Stefan , Pan, Shuchong, Zheng, Ye , Malany, Siobhan , Burnett, John C. , Maloney, Patrick R , Sangaralingham, S. Jeson

Mayo Clinic

Proceedings of the National Academy of Sciences | December 20, 2021 | Volume: 118 | Issue: 52 | Pages: No page available

10.1073/pnas.2109386118 | PMID 34930837 Get It

Significance The particulate guanylyl cyclase A receptor (GC-A), via its endogenous cardiac-derived hormones atrial natriuretic peptide (ANP) and b-type natriuretic peptide (BNP), plays a pivotal role in maintaining intravascular volume, arterial pressure, cardiovascular structure, function, and, more recently, metabolic homeostasis. As such, therapies to potentiate GC-A signaling via peptide augmentation have yielded promising results in clinical trials. A major breakthrough in GC-A therapeutics would be a small molecule that sensitizes the GC-A receptor to endogenous ANP or BNP, which to date does not exist. Here, we report the development of an orally bioavailable, small molecule positive allosteric modulator of GC-A that exhibits therapeutic activity in human hypertension and heart failure ex vivo.
Hepatitis E virus Infection in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review and Meta-Analysis
Trongtorsak, Angkawipa , Chaisidhivej, Natapat, Kim, Jinah, Thongprayoon, Charat , Cheungpasitporn, Wisit , Hansrivijit, Panupong , Kim, Jinah , Thongprayoon, Charat , Hansrivijit, Panupong , Cheungpasitporn, Wisit , Yadav, Kritika

Mayo Clinic

Journal of Investigative Medicine | December 20, 2021 | Volume: 70 | Issue: 3 | Pages: 853-858

10.1136/jim-2021-002102 | PMID 34930797 Get It

Although most patients with hepatitis E virus (HEV) infection are asymptomatic or have mild symptoms, its infection is generally underdiagnosed and overlooked. In immunocompromised patients, HEV infection can lead to acute liver failure and death. However, the clinical evidence of HEV infection in hematopoietic stem cell transplant (HSCT) recipients is scarce; thus, we conducted this systematic review and meta-analysis to assess the prevalence of HEV infection in this population. We searched MEDLINE, EMBASE, and the Cochrane Library databases from inception through October 2020 to identify studies that reported the prevalence of HEV infection among HSCT recipients. HEV infections were confirmed by HEV-IgG/IgM or HEV-RNA assay. A total of 1977 patients from nine studies with a follow-up time up to 40 months were included in the final analysis. The pooled prevalence of positive HEV-RNA was 3.0% (95% CI 2.3% to 4.0%). The pooled prevalence of positive HEV-IgG was 10.3% (95% CI 4.5% to 21.8%). The pooled prevalence of de novo HEV infection was 2.9% (95% CI 1.8% to 4.5%). Age and male gender were not associated with HEV-RNA or HEV-IgG positivity in the meta-regression analysis. In conclusion, the prevalence of HEV-IgG in HSCT recipients was about 10%, while the prevalence of HEV-RNA was only 3%. However, further studies that focus on the clinical outcomes in this population are warranted.